New Cardiovascular Risk Factor Identified

ITASCA, IL, Nov 02 (MARKET WIRE) --
AtCor Medical (ASX: ACG) the developer and marketer of the SphygmoCor(R)
system which measures central blood pressure and arterial stiffness
noninvasively, today announced the publication of a key National
Institutes of Health (NIH)-funded study(1) using SphygmoCor in the
Journal of the American College of Cardiology (JACC).

The study "High Central Pulse Pressure Is Independently Associated with
Adverse Cardiovascular Outcome" followed 2,405 participants over a period
averaging 5.6 years. It was found that when central pulse pressure
exceeded 50 mm Hg, the risk of a cardiovascular event sharply increased.
No similar predictive relationship was found with standard cuff blood
pressure measurements taken at the arm. Patients in the highest quartile
of central pulse pressure (50mm Hg or > ) were 70% more likely to
experience cardiovascular events than those in the lowest quartile ( <
31mm Hg).

The study concludes that central pulse pressure greater than 50 mm Hg
predicts adverse cardiovascular outcome and that central pulse pressure
may serve as a target for intervention strategies in patient care.

"It is not surprising that central blood pressure correlates better with
target organ damage and cardiovascular outcomes than brachial blood
pressure does, because it more accurately reflects vascular load on the
left ventricle and cerebral and coronary vasculature," the study authors
stated.

"The publication of this study is a major event for AtCor Medical," said
Duncan Ross, AtCor Medical's President and CEO. "Many studies have
established that increased central pressure is associated with increased
cardiovascular risk -- and that central pressure can be reduced with drug
therapy and lifestyle changes. But now, for the first time, clinicians
have a specific central pressure target for use in intervention
strategies.

"The evidence continues to accumulate and is very compelling; reliance on
brachial cuff pressures to assess risk and develop intervention strategies
masks many patients' true risk and when brachial cuff and central
pressures are included in the same model, brachial cuff pressures cease
to be statistically significant. In patient care and in pharmaceutical
trials it is critically important to assess central pressures."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of
cardiovascular risk and management of cardiovascular disease. Its
technology allows researchers and clinicians to measure central blood
pressure non-invasively. The company's SphygmoCor system visibly
identifies the effects of reflected blood pressure in the central aortic
pressure wave, effects which cannot be detected with standard blood
pressure monitoring. More than 2,100 SphygmoCor systems are currently in
use worldwide at major medical institutions, in clinical trials with
leading pharmaceutical companies and in physicians' offices. The company's
technology has been featured in over 400 peer-reviewed studies published
in leading medical journals. AtCor has operations in Australia, the United
States and Europe. For further information, please visit our web site at
www.atcormedical.com

(1) High Central Pulse Pressure Is Independently Associated With Adverse
Cardiovascular Outcome: The Strong Heart Study, Mary J. Roman et al.
Journal of the American College of Cardiology Vol. 54, No.18, 2009

For further information, please contact:

Duncan Ross
AtCor Medical CEO
+1 (630) 228 8874

Peter Manley
AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Larry Watts
AtCor Medical
+1 (630) 228 8875

Copyright 2009, Market Wire, All rights reserved.

-0-